RBC Capital Maintains Outperform Rating on Revolution Medicines, Sets $260 Target
RBC Capital maintained its Outperform rating on Revolution Medicines and a $260 price target. The target implies 38.0% upside from the Oct. 13 close of $188.44.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results.
RBC Capital maintains Revolution Medicines Outperform rating
RBC Capital maintains Outperform on Revolution Medicines
RBC Capital maintained an Outperform rating on Revolution Medicines.